It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company's experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patients ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Shares in Novo Nordisk plunged 20% on Friday. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and ...

Novo Nordisk's CargiSema Phase III trial showed significant weight loss but failed reach ambitious targets set by management, leading to a 20% stock decline. CagriSema may still be competitive to ...

Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on Friday, the sharpest one ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value ...

As a private company with Novo Holdings’ partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients they serve, and ultimately create ...

Novo Nordisk A/S (NVO) investors were hit by a train as the leading diabetes and obesity drugs maker's recent CagriSema study didn't impress as its performance came in markedly below its ...

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...